p21活化激酶5在骨肉瘤组织中的表达及临床意义

doi:10.3969/j.issn.1007-3969.2014.01.001

中国癌症杂志 ›› 2014, Vol. 24 ›› Issue (1): 1-7.doi: 10.3969/j.issn.1007-3969.2014.01.001

p21活化激酶5在骨肉瘤组织中的表达及临床意义

田聪¹,汤丽娜²,林峰²,沈赞²,陈杰³,姚阳²,闵大六²

1.苏州大学医学部研究生院，江苏苏州 215131 ；
2.上海交通大学附属第六人民医院肿瘤内科，上海 200233 ；
3.上海交通大学附属第六人民医院病理科，上海 200233

出版日期:2014-01-30 发布日期:2014-02-14
通信作者: 闵大六　E-mail:mindaliu@csco.org.cn
基金资助:
国家自然科学基金面上项目资助(No：81172548)

Expression and clinical significance of PAK5 protein expression in osteosarcoma

TIAN Cong¹,TANG Li-na²,LIN Feng²,SHEN Zan²,CHEN Jie³,YAO Yang²,MIN Da-liu²

1.Department of Medical School of Soochow University, Suzhou Jiangsu 215131, China;
2.Department of Medical Oncology, the Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China;
3.Department of pathology, the Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China

Published:2014-01-30 Online:2014-02-14
Contact: MIN Da-liu E-mail: mindaliu@csco.org.cn

摘要/Abstract

摘要： 背景与目的：p21活化激酶5(p21-activated kinase 5，PAK5)为PAKs家族中新近发现的成员，在细胞骨架重组，细胞生长、增殖、分化，基因转录及细胞凋亡等一系列的细胞功能中发挥重要作用。近来有研究发现PAK5参与了胃癌、肠癌等恶性肿瘤的发生发展过程。本研究旨在探讨PAK5在人骨肉瘤组织中的表达及其与骨肉瘤患者预后的关系。方法：应用免疫组化方法检测92例骨肉瘤活检样本石蜡组织中PAK5蛋白的表达，33例骨巨细胞瘤样本作为阴性对照，并分析PAK5表达与骨肉瘤患者临床参数及生存之间的关系。结果：骨肉瘤组织中PAK5蛋白表达阳性率为71.7%(66/92)，骨巨细胞瘤中未见PAK5表达(0/33)。PAK5表达与患者的性别、年龄、肿瘤部位、肿瘤大小、组织学类型、局部复发等无关，而与Enneking分期、肿瘤坏死率和肺转移相关，且PAK5高表达能降低化疗的有效率。单因素分析表明，肿瘤大小、Enneking分期、局部复发、肺转移及PAK5表达水平是影响骨肉瘤患者预后的因素。多因素分析显示，PAK5表达水平(P=0.001)及肺转移(P=0.015)是影响骨肉瘤预后相关的独立的重要因素。结论：PAK5表达水平与Enneking分期、肿瘤坏死率和肺转移相关；PAK5的表达可作为骨肉瘤预后预测的指标；PAK5高表达能降低化疗的有效率。

关键词: 骨肉瘤, PAK5, 预后, 免疫组织化学

Abstract: Background and purpose: p21-activated kinase 5 (PAK5) is a recently identified member of PAKs that regulate many intracellular processes such as cytoskeleton remodeling, cell proliferation, cell differentiation,gene transcription and cell apoptosis. Recently, studies found that PAK5 was overexpressed in some cancer such as gastric and colon cancer. However, the expression status and biological function of PAK5 in osteosarcoma are not clearly known. The objective of this study was to investigate the expression of PAK5 in osteosarcoma tissue and their relationships with the prognosis of osteosarcoma. Methods: The expression of PAK5 was detected by using immunohistochemical method in 92 specimens of human osteosarcoma tissues and 33 cases of osteoclastoma tissue, respectively. Results: The positive rate of PAK5 was 71.7% (66/92) in all the 92 cases of osteosarcoma. PAK5 expressions were not related to clinical variables such as gender, age, tumor location, tumor size, histological type and local recurrence, but significantly related to Enneking grade, tumor cell necrosis rate and lung metastasis, and the high expression of PAK5 may reduce the efficiency of chemotherapy. Survival analysis indicated that high expression of PAK5 correlated with poor prognosis of patients with osteosarcoma. Univariate survival analysis showed that the significant prognostic factors were tumor size, Enneking grade, local recurrence, lung metastasis and expression levels of PAK5. COX multivariate regression identified that the PAK5 expression levels (P=0.001) and lung metastasis (P=0.015) were independent prognostic factors of patients with osteosarcoma. Conclusion: The positive expressions of PAK5 closely correlate with Enneking grade, tumor cell necrosis rate and lung metastasis. Detection of PAK5 may be used as a molecular marker for prognosis of osteosarcoma. The high expression of PAK5 may reduce the efficiency of chemotherapy.

Key words: Osteosarcoma, PAK5, Prognosis, Immunohistochemistry

田聪,汤丽娜,林峰,沈赞,陈杰,姚阳,闵大六. p21活化激酶5在骨肉瘤组织中的表达及临床意义[J]. 中国癌症杂志, 2014, 24(1): 1-7.

TIAN Cong,TANG Li-na,LIN Feng,SHEN Zan,CHEN Jie,YAO Yang,MIN Da-liu. Expression and clinical significance of PAK5 protein expression in osteosarcoma[J]. China Oncology, 2014, 24(1): 1-7.

[1]	林艺, 王策, 康勋, 康庄, 陈峰, 江波, 李文斌. 胶质母细胞瘤复发相关基因的筛选、表达和临床预后分析[J]. 中国癌症杂志, 2022, 32(1): 13-23.
[2]	徐　然, 王馨悦, 冯麟媛, 韩安娜, 王艺璇, 杨万山, 刘　超 . 神经胶质瘤中NCAPD2的表达水平及生物学意义[J]. 中国癌症杂志, 2021, 31(9): 789-798.
[3]	马祎菲, 梁新军, 魏少忠 . 炎症与免疫指标在可切除性结直肠癌中的预后价值[J]. 中国癌症杂志, 2021, 31(9): 845-851.
[4]	雷雅洁, 高　毅, 王治洁, 程　玺, 杨雨菲, 周宏宇, 陈丽华, 陈伊新, 李浩然, 李子庭, 吴小华 . 早期卵巢癌（Ⅰ C ~ⅡA）患者腹主动脉旁淋巴结清扫术对预后影响的临床分析[J]. 中国癌症杂志, 2021, 31(8): 740-745.
[5]	高鹤丽, 徐　近, 虞先濬. 分化好的胃肠胰神经内分泌瘤G3的诊治新进展[J]. 中国癌症杂志, 2021, 31(7): 567-573.
[6]	巩润泽, 胡海燕. CCL2在骨肉瘤组织中的表达及其临床意义[J]. 中国癌症杂志, 2021, 31(6): 455-459.
[7]	彭子珊, 孔　辉, 鲍　真, 赵红杏, 刘　鑫, 卢韶华. 83例多发肺腺癌患者的临床病理学特征分析[J]. 中国癌症杂志, 2021, 31(5): 408-418.
[8]	肖　锋, 肖静文, 邵建国, 陈丽燕, 顾春燕 . PD-1在肝细胞癌肿瘤浸润淋巴细胞中的表达及与预后的相关性[J]. 中国癌症杂志, 2021, 31(5): 419-427.
[9]	王春建 , 聂　刚 , 毛　艳 . TRIP6在乳腺癌中的作用及其机制研究[J]. 中国癌症杂志, 2021, 31(3): 161-169.
[10]	武元元 , 王　军 , 刘勤江 , 张　明 . 甲状腺未分化癌的预后因素分析及治疗决策[J]. 中国癌症杂志, 2021, 31(3): 212-220.
[11]	冯润林 , 华　结 , 奎　翔 , 李如懿 , 易晓佳 , 王　燕 , 陶燕萍 . 转移性心包黏液样脂肪肉瘤1例报道并文献复习[J]. 中国癌症杂志, 2021, 31(3): 227-230.
[12]	杨柳松, 祝迎锋, 唐剑敏 . 上皮样胶质母细胞瘤10例报告并文献复习[J]. 中国癌症杂志, 2021, 31(2): 114-120.
[13]	丁平安, 张志栋, 杨沛刚, 林叶成, 田　园, 徐校胜, 吴　娟, 刘　颖, 郭洪海, 刘　洋, 王　冬, 檀碧波, 李　勇, 赵　群 . 胃癌脑膜转移的临床病理学特征及预后分析[J]. 中国癌症杂志, 2021, 31(2): 126-135.
[14]	周宏宇, 李浩然, 程　玺, 陈丽华, 杨雨菲, 常　彬 . 11例卵巢高钙血症型小细胞癌临床分析并文献复习[J]. 中国癌症杂志, 2021, 31(2): 136-142.
[15]	李　飞, 宋　媛, 李　芳, 朱希燕, 何　明 . 食管胃交界部腺癌SiewertⅠ型和Ⅱ型胸外科手术治疗效果及预后研究[J]. 中国癌症杂志, 2021, 31(2): 143-150.

p21活化激酶5在骨肉瘤组织中的表达及临床意义

Expression and clinical significance of PAK5 protein expression in osteosarcoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价